



Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

March 16, 2022

TORONTO--(BUSINESS WIRE)-- [Cybin](#) Inc. ([NEO:CYBN](#)) (NYSE American:CYBN) ("**Cybin**" or the "**Company**"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET.

Mr. Drysdale's presentation will be available on demand beginning at 9:00 a.m. ET on Monday, March 28th. To attend, please [register here](#) to access the conference. To listen to the presentation, please [click here](#) to access the webcast. The archived webcast will also be available on the Company's investor relations website on the [Events & Presentations](#) page.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.



Investor & Media:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Source: Cybin Inc.